News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Anthony Lucci, MD

Articles by Anthony Lucci, MD

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

ByAttilla Soran,Berk Goktepe,Berkay Demirors,Serdar Ozbas,Efe Sezgin,Jamila Al-Azhri,Shruti Zaveri,S. Meas,Anthony Lucci, MD,Priscilla F. Mcauliffe, MD, PhD

April 21st 2024

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers

ByCarolyn Hall, PhD,Anthony Lucci, MD

January 15th 2011

The authors of “How Long Have I Had My Cancer, Doctor?” have addressed a question often contemplated by patients when they receive a diagnosis of cancer.

Latest Updated Articles

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers
Published: January 15th 2011 | Updated:

Trending on CancerNetwork

New CAR T-Cell Therapy Earns FDA Breakthrough Status in T-Cell Malignancies

Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma

FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer

FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals

Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis